Published Technical Disclosure Archive

AI-Driven Chimeric Animal Inflammation Management System

Publication ID: 24-11856927_0003_PTD
Published: October 26, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “AI-Driven Chimeric Animal Inflammation Management System,” Published Technical Disclosure No. 24-11856927_0003_PTD, Published October 26, 2025, available at https://archive.pr1or.art/24-11856927_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,856,927.

Background and Problem Solved

The original patent addressed the issue of immune response and inflammation in chimeric animals after birth. However, it did not provide a holistic solution for real-time monitoring, personalized treatment, and data management. The present invention solves this problem by synergistically combining AI, IoT, blockchain, and novel biomaterials to create a powerful system for managing inflammation in chimeric animals.

Novelty and Inventive Step

The new claims introduce a synergistic combination of AI, IoT, blockchain, and novel biomaterials, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a comprehensive and personalized system for managing inflammation in chimeric animals.

Alternative Embodiments and Variations

Alternative embodiments could include using different AI algorithms, IoT devices, or blockchain platforms. Variations could involve integrating additional technologies, such as gene editing or nanotechnology, to further enhance the system's capabilities.

Potential Commercial Applications and Market

The invention has significant commercial potential in the animal health industry, particularly in the fields of xenotransplantation, regenerative medicine, and precision agriculture. The target market includes pharmaceutical companies, research institutions, and animal breeding organizations.

CPC Classifications

SectionClassGroup
A A01 A01K67/0271
A A61 A61K31/573
A A61 A61P37/06
A A01 A01K2217/05
A A01 A01K2217/075
A A01 A01K2227/105
A A01 A01K2267/035
C C12 C12N15/09

Field of Art

Veterinary biotechnology, genetic engineering, and chimeric animal research, with expertise in immunological monitoring, stem cell transplantation, and personalized medical interventions for genetically modified organisms

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in veterinary medicine or biotechnology, familiar with genetic chimera development, immunological tracking technologies, and emerging computational approaches to medical monitoring

Obviousness Rationale

A person skilled in the art would recognize that integrating modern computational technologies like AI, IoT, and blockchain with the source patent's chimeric animal inflammation management approach represents a predictable technological extension. The core principles of monitoring, tracking, and intervening in chimeric animal immune responses remain consistent, with technological platforms serving as interchangeable implementation mechanisms. The PTD's variations represent standard engineering design choices that would be obvious to a skilled practitioner seeking enhanced monitoring and treatment capabilities.

Obvious Combinations & Variations

Source Patent Element
Method for obtaining an adult individual from a chimeric animal fetus with no substantial inflammation
PTD Variation
AI-powered monitoring system tracking inflammation levels in real-time
Obviousness Reasoning
Predictable application of computational monitoring to existing medical tracking methodologies, representing a known technique for enhancing diagnostic precision
Source Patent Element
Administering anti-inflammatory agents before occurrence of immune response
PTD Variation
Blockchain-based health record system for tracking treatment interventions
Obviousness Reasoning
Standard data management approach for medical records, representing an obvious technological enhancement to existing treatment protocols
Source Patent Element
Identifying individuals prone to inflammation after birth
PTD Variation
Machine learning algorithm integrated with genomic analysis for predicting immune response risks
Obviousness Reasoning
Applying computational predictive techniques to genetic risk assessment represents a known and expected technological progression in personalized medicine
Source Patent Element
Chimeric animal with potential for immune system variations
PTD Variation
IoT-enabled wearable device for continuous inflammation monitoring
Obviousness Reasoning
Implementing wireless sensor technologies for biological tracking is a predictable engineering solution with well-understood implementation strategies
Source Patent Element
Method for managing post-birth inflammatory responses
PTD Variation
Novel biomaterial composition combined with AI-driven personalized treatment planning
Obviousness Reasoning
Combining material science with computational treatment optimization represents a standard approach to developing more precise medical interventions
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11856927 and the disclosed technological variations, a person having ordinary skill in the art would find the claimed innovations obvious and lacking inventive step. The integration of computational technologies with existing chimeric animal inflammation management represents predictable engineering design choices that do not rise to the level of non-obvious technological advancement, thus rendering potential derivative claims unpatentable under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,856,927
TitleFinding and treatment of inflammation after birth in chimeric animal
Assignee(s)The University of Tokyo